Merkel Cell Carcinoma Clinical Trial
— CARADERMOfficial title:
French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : - to provide epidemiological, clinical and socio-economic characteristics of patients - to identify new clinical or epidemiological prognostic factors for these rare cancers - to evaluate the impact of various treatments on outcomes
| Status | Recruiting |
| Enrollment | 9000 |
| Est. completion date | December 31, 2025 |
| Est. primary completion date | December 31, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma Exclusion Criteria: - Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma - Patients refusal |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Amiens Picardie | Amiens | |
| France | CHU Angers | Angers | |
| France | CH Annecy Gennevois | Annecy | |
| France | CHU Besançon | Besançon | |
| France | CHU Avicenne | Bobigny | |
| France | CHU Ambroise Paré | Boulogne-Billancourt | |
| France | CHU de Brest | Brest | |
| France | CHU de Caen | Caen | |
| France | CHU de Clermont Ferrand | Clermont Ferrand | |
| France | CHU Bocage | Dijon | |
| France | CHU de Grenoble | Grenoble | |
| France | CH Le Mans | Le Mans | |
| France | CHU de Limoges | Limoges | |
| France | Centre Léon Bérard | Lyon | |
| France | Hôpital La Timone | Marseille | |
| France | Hôpital St Eloi | Montpellier | |
| France | CHU de Nancy | Nancy | |
| France | CHU Nantes - Place Alexis Ricordeau | Nantes | |
| France | CHU de Nice | Nice | |
| France | CHR d'Orleans | Orléans | |
| France | CHU Bichat | Paris | |
| France | CHU Cochin | Paris | |
| France | CHU St Louis | Paris | |
| France | CHU de Bordeaux | Pessac | |
| France | Centre hospitalier Lyon Sud | Pierre-benite | |
| France | CHU de Pointe à Pitre | Pointe À Pitre | |
| France | CHU de Poitiers | Poitiers | |
| France | CHU de Reims | Reims | |
| France | CHU de Rennes | Rennes | |
| France | CHU de Rouen | Rouen | |
| France | CHU de Strasbourg | Strasbourg | |
| France | CHU de Toulouse - Larrey | Toulouse | |
| France | CHU de Tours | Tours | |
| France | Institut Gustave Roussy | Villejuif |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Lille |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence and natural history of the 3 types of rare skin cancers | 10 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT04705389 -
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
|
N/A | |
| Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05429866 -
Immunological Variables Associated to ICI Toxicity in Cancer Patients
|
Phase 2 | |
| Completed |
NCT04393753 -
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
|
Phase 2 | |
| Completed |
NCT03545334 -
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study
|
N/A | |
| Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04291885 -
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02054884 -
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04975152 -
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06039033 -
Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
|
||
| Completed |
NCT02514824 -
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06056895 -
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
| Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06086288 -
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
|
Phase 2 | |
| Recruiting |
NCT04157985 -
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
|
Phase 3 |